Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Increased expression of miR-21 and PI3K/Akt/VEGF related genes, along with a reduced expression of PTEN was observed in the retinal tissues of DR rats. 31759996 2020
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE The concentrations of both biomarkers showed escalating trends with the severity of DR. Two concentration thresholds of LCN1 and VEGF that indicate proliferative DR were determined out of 24 clinical samples based on the receiver operating characteristic curves. 31848562 2020
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Meta-GWAS have reported numerous single-nucleotide polymorphisms (SNPs) associated with T2D; however, no loci, achieving genome-wide significance has been reported for DR. Vascular endothelial growth factor A (VEGFA) and insulin-like growth factor 1 (IGF1) are considered as potential genetic candidates involved in T2D and DR progression. 31473834 2020
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE To attribute data on changes in diabetic retinopathy (DR) severity during treatment of diabetic macular edema (DME) with vascular endothelial growth factor inhibitors (anti-VEGF), this study aimed to (1) examine the correlation between oxygen saturations in retinal vessels and the number of DR lesions on ultra-wide field color fundus photographs prior to anti-VEGF treatment and (2) compare changes in oxygen saturations in retinal vessels with changes in the number of DR lesions after a loading dose of three monthly intravitreal injections of 2.0 mg of aflibercept. 31715608 2020
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE In VEGF-induced DR rats, ITR and CS-ITR-NLCs were found to exhibit an antineovascularization effect by targeting VEGF<sub>165</sub>. 30835139 2020
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE IL-27 suppresses VEGFA production by DR patient macrophages even in the presence of IL-1β challenge indicating a potential therapeutic use of IL-27 in the clinic. 30007476 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Low expression of microRNA-15b in retinal capillary endothelial cells and pericytes of diabetic rats promotes the development of diabetic retinopathy by up-regulating VEGFA. 31364104 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE We exposed human retinal microvascular endothelial cells (RMVEC) to VEGF as an in vitro model of DR in the presence and absence of T1R3 agonist sucralose. 30353220 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Indeed, VEGF is known to play important neuroprotective actions; therefore, in the early phases of DR, it may be released in response to neuronal suffering, and it would act as a double-edged weapon inducing both neuroprotective and vasoactive effects. 31787868 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Compared with IL-12 and blank nanoparticles, IL-12-PNP showed better inhibitory efficacy against VEGF-A and MMP-9 expression in rat endothelial cells and DR mouse retina. 31496691 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE The downstream exacerbating factors including vascular endothelial growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1) and matrix metalloproteinase 2 (MMP2), which are implicated in the pathogenesis of DR and closely related to oxidative stress were also analyzed. 30662833 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. 30878488 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Systemic Factors Related to Intraocular Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Diabetic Retinopathy. 31396410 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD). 31055948 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Nowadays, the principal treatment options for DR are laser photocoagulation, vitreoretinal surgery, or intravitreal injection of drugs targeting vascular endothelial growth factor. 30987058 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production. 30999027 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Using ocular clinical samples and animal disease models, we elucidated molecular mechanisms in which tissue RAS excites the expression of vascular endothelial growth factor (VEGF)-A responsible for retinal inflammation and angiogenesis, the two major pathological events in diabetic retinopathy (DR). 29575757 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE Thus, combining anti-VEGF therapy with other new therapies targeting these pathophysiological pathways of DR may further optimize treatment outcomes. 31557880 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE These clinical trial data indicate that intraocular inhibition of VEGF is a rational approach for the management of DR. 31669065 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR). 31173913 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 Biomarker disease BEFREE However, miR-15a could downregulate VEGF and Robo4 to ameliorate DR development. 30980286 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Hyperglycemia invoke number of pathways resulting in development of diabetic retinopathy (DR), including protein kinase C activation, increased expression of VEGF, advanced glycation end product (AGEs) formation and activation of polyol pathway, among which the pathophysiology of aldose reductase (ALR2) of the polyol pathway is evident by more than a decade of research. 30551523 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 GeneticVariation disease BEFREE Amongst all the DVC, D allele of the VEGF polymorphism had a significantly increased risk of diabetic retinopathy (DR) (OR = 1.31; p = 0.033) irrespective of the duration of diabetes, BMI, the glycemia control expressed by HbA1c, renal function, lipid values or applied treatment. 30654317 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Overall, serum VEGF levels were significantly higher in DR patients (SMD: 0.74, 95% CI: 0.44-1.03) than those in NDR patients, while plasma VEGF levels were not in the comparison (SMD: 0.40, 95% CI: -0.13-0.92). 31019585 2019
CUI: C0011884
Disease: Diabetic Retinopathy
Diabetic Retinopathy
0.400 AlteredExpression disease BEFREE Elevated expression of photoreceptor-secreted RBP3 may have a role in protection against the progression of DR due to hyperglycemia by inhibiting glucose uptake via GLUT1 and decreasing the expression of inflammatory cytokines and VEGF. 31270273 2019